Actinogen is advancing a revolutionary oral therapeutic, Xanamem^®, through pivotal trials to transform treatment for Alzheimer’s disease and major depressive disorder. Our vision is to improve lives by targeting brain cortisol with precision and innovation.

ACW announces AGM details & director nomination closing date

ACW’s Annual General Meeting will be held at 11am on Wednesday,
19 November 2025 at the offices of K&L Gates, Level 31, 1 O’Connell St Sydney NSW 2000.
The closing date for the receipt of nominations from those wishing to be considered for election as a director is 5pm Wednesday, 8 October 2025 (Sydney time).

ACW announces successful FDA meeting on Alzheimer's program

Actinogen has announced the successful conduct of its scheduled Type C meeting on Alzheimer’s disease (AD) with the US FDA.

Actinogen and the FDA reached a common understanding of the pathway to marketing approval in AD – meaning agreement on regulatory starting materials in drug substance synthesis, the design of one additional pivotal clinical trial and the limited number of ancillary clinical pharmacology trials and nonclinical studies required.

ACW launches new Investor Hub portal to boost investor engagement

Actinogen has announced the launch of a new Investor Hub for dedicated investor engagement.

The site provides shareholders the opportunity to view recent ASX announcements, shareholder news and key company updates all in one place. It’s easy to post questions and share feedback through the Q&A function accompanying each piece of content to engage with the leadership team and gain a better understanding of the company’s updates.

ACW announces successful Xanamem pharmacokinetics trial

Actinogen has announced the successful completion of a recent trial of the intended commercial tablet formulation of Xanamem. The result indicates that 10 mg once daily Xanamem remains the target therapeutic dose for the clinical program.

ACW releases FY2025 results and annual report

Actinogen has released its 2025 financial results and annual report for the year ended 30 June 2025.

View Appendix 4E and 2025 annual report announcement

ACW CEO presents to investors at Bisoshares Summit

ACW CEO Dr Steven Gourlay presents to investors at the 2025 Bioshares Biotech Summit in Hobart, a key event for leading emerging ASX-listed lifescience and biotech organisations.
Dr Gourlay’s Q&A style presentation addresses important investor questions in ACW’s drug development story to date.